Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
October 04 2021 - 7:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of October 2021
Commission File Number: 001-39137
AnPac Bio-Medical
Science Co., Ltd.
(Registrant’s name)
801 Bixing Street, Bihu County
Lishui, Zhejiang Province 323006
The People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F. Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b) (1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b) (7): ¨
Explanatory Note:
The Registrant is filing this Report on Form 6-K
to announce that its cancer differentiation analysis (CDA) technology has shown a strong correlation between CDA score and risk of cancer and diseases.
Attached as an exhibit to this Report on Form 6-K
is the press release dated October 4, 2021.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
AnPac Bio-Medical Science Co., Ltd.
|
|
|
(Registrant)
|
|
|
|
Date: October 4, 2021
|
By:
|
/s/ Chris Chang Yu
|
|
Name:
|
Dr. Chris Chang Yu
|
|
Title:
|
Chairman of the Board of Directors and Chief Executive Officer
|
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Apr 2023 to Apr 2024